IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS: MECHANISMS, CLINICAL EFFICACY, BIOMARKER-GUIDED PATIENT SELECTION, AND IMMUNE-RELATED ADVERSE EVENTS. Journal of Multidisciplinary Sciences and Innovations, [S. l.], v. 5, n. 03, p. 1709–1714, 2026. DOI: 10.55640/. Disponível em: https://ijmri.de/index.php/jmsi/article/view/6590. Acesso em: 16 apr. 2026.